Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +3.31% | +1.93% | +69.29% | +129.27% | 55.78B | |
| -1.32% | +16.55% | +89.14% | +101.41% | 55.66B | |
| -11.62% | +2.92% | -12.40% | -13.59% | 23.84B | |
| +5.89% | +4.66% | +6.24% | +406.71% | 22.7B | |
| +4.45% | +8.43% | +37.08% | -29.19% | 16.12B | |
| -1.57% | +6.31% | +23.83% | +185.61% | 13.64B | |
| +5.51% | +22.37% | +171.85% | +333.54% | 14.8B | |
| +1.90% | +4.86% | +77.89% | +133.06% | 12.16B | |
| -11.21% | +6.49% | +157.88% | +161.20% | 11.85B | |
| Average | +1.33% | +6.15% | +68.98% | +156.45% | 25.17B | |
| Weighted average by Cap. | +1.28% | +5.02% | +66.02% | +142.53% |
Employees
51
